Daneshpazhooh Maryam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7669984/publications.pdf

Version: 2024-02-01

209 papers

3,736 citations

172386 29 h-index 197736 49 g-index

213 all docs

213 docs citations

times ranked

213

2771 citing authors

#	Article	IF	CITATIONS
1	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology, 2020, 82, 575-585.e1.	0.6	224
2	Pemphigus: Analysis of 1209 cases. International Journal of Dermatology, 2005, 44, 470-476.	0.5	212
3	Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. Journal of the American Academy of Dermatology, 2007, 57, 622-628.	0.6	189
4	Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1900-1913.	1.3	159
5	Mucocutaneous Findings in 100 Children with Down Syndrome. Pediatric Dermatology, 2007, 24, 317-320.	0.5	75
6	Tongue lesions in psoriasis: a controlled study. BMC Dermatology, 2004, 4, 16.	2.1	73
7	Pruritus in hemodialysis patients. BMC Dermatology, 2005, 5, 7.	2.1	71
8	Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatology, 2006, 6, 3.	2.1	70
9	Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 1319-1324.	1.3	70
10	Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. International Immunopharmacology, 2018, 54, 131-138.	1.7	70
11	Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires. Journal of Dermatology, 2012, 39, 141-144.	0.6	64
12	International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. British Journal of Dermatology, 2018, 179, 30-41.	1.4	62
13	Updated <scp>S2</scp> K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (<scp>EADV</scp>). Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1689-1704.	1.3	61
14	Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1285-1292.	1.3	53
15	Pemphigus Disease Activity Measurements. JAMA Dermatology, 2014, 150, 266.	2.0	53
16	Treatment considerations for patients with pemphigus during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2020, 82, e235-e236.	0.6	53
17	Pemphigus and associated environmental factors: a case?control study. Clinical and Experimental Dermatology, 2007, 32, 256-260.	0.6	51
18	Pimecrolimus Cream, 1%, vs Hydrocortisone Acetate Cream, 1%, in the Treatment of Facial Seborrheic Dermatitis: A Randomized, Investigator-Blind, Clinical Trial. Archives of Dermatology, 2006, 142, 1065.	1.7	48

#	Article	IF	Citations
19	Spectrum of autoimmune bullous diseases in Iran: a 10â€year review. International Journal of Dermatology, 2012, 51, 35-41.	0.5	48
20	Autosomal recessive congenital ichthyosis: Genomic landscape and phenotypic spectrum in a cohort of 125 consanguineous families. Human Mutation, 2019, 40, 288-298.	1.1	43
21	Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients. Journal of Dermatological Treatment, 2019, 30, 598-604.	1.1	43
22	Cryotherapy in the treatment of pyogenic granuloma. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 060609033000012-???.	1.3	41
23	Pemphigus and pregnancy: A 23-year experience. Indian Journal of Dermatology, Venereology and Leprology, 2011, 77, 534.	0.2	41
24	Cervicovaginal involvement in pemphigus vulgaris: a clinical study of 77 cases. British Journal of Dermatology, 2008, 158, 478-482.	1.4	40
25	Frontal fibrosing alopecia: An update on the hypothesis of pathogenesis and treatment. International Journal of Women's Dermatology, 2019, 5, 116-123.	1.1	40
26	Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase <scp>II</scp> clinical trial. International Journal of Dermatology, 2013, 52, 862-867.	0.5	37
27	Pemphigus vulgaris in Iran: a clinical study of 140 cases. International Journal of Dermatology, 2007, 46, 1166-1170.	0.5	35
28	Validity of trichoscopy in the diagnosis of primary cicatricial alopecias. International Journal of Dermatology, 2016, 55, 1106-1114.	0.5	34
29	BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid. Archives of Dermatological Research, 2018, 310, 255-259.	1.1	31
30	Nail changes in pemphigus vulgaris. International Journal of Dermatology, 2008, 47, 1141-1144.	0.5	29
31	Serum and salivary desmoglein 1 and 3 enzymeâ€linked immunosorbent assay in pemphigus vulgaris: correlation with phenotype and severity. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 275-280.	1.3	29
32	Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission. Journal of the American Academy of Dermatology, 2016, 74, 1160-1165.	0.6	29
33	Dermopathy and Retinopathy in Diabetes: Is There an Association?. Dermatology, 2007, 214, 133-136.	0.9	28
34	Iranian guideline for rituximab therapy in pemphigus patients. Dermatologic Therapy, 2019, 32, e13016.	0.8	28
35	Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?. Archives of Dermatological Research, 2019, 311, 63-69.	1.1	28
36	Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study. Journal of the American Academy of Dermatology, 2021, 84, 1098-1100.	0.6	28

#	Article	IF	Citations
37	Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study. International Immunopharmacology, 2021, 96, 107755.	1.7	28
38	The course of melanoma-associated vitiligo: report of a case. Melanoma Research, 2006, 16, 371-373.	0.6	27
39	Thyroid autoimmunity and pemphigus vulgaris: Is there a significant association?. Journal of the American Academy of Dermatology, 2010, 62, 349-351.	0.6	27
40	Drug-induced pemphigus: A systematic review of 170 patients. International Immunopharmacology, 2021, 92, 107299.	1.7	27
41	Lupus vulgaris at the site of BCG vaccination: report of three cases. Clinical and Experimental Dermatology, 2009, 34, e167-e169.	0.6	26
42	Outcome of pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 580-584.	1.3	23
43	An atypical presentation of erythema elevatum diutinum involving palms and soles. International Journal of Dermatology, 2009, 48, 73-75.	0.5	23
44	A study on plucked hair as a substrate for direct immunofluorescence in pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 129-131.	1.3	23
45	Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris. Clinical and Experimental Dermatology, 2014, 39, 41-47.	0.6	23
46	Pathogenic and protective roles of cytokines in pemphigus: A systematic review. Cytokine, 2020, 129, 155026.	1.4	23
47	International Dermoscopy Society criteria for nonâ€neoplastic dermatoses (general dermatology): validation for skin of color through a Delphi expert consensus. International Journal of Dermatology, 2021, , .	0.5	23
48	Dermoscopic findings in 126 patients with alopecia areata: A cross-sectional study. International Journal of Trichology, 2018, 10, 118.	0.1	23
49	Traumaâ€induced pemphigus: a case series of 36 patients. JDDG - Journal of the German Society of Dermatology, 2016, 14, 166-171.	0.4	22
50	Paradoxical reaction to rituximab in patients with pemphigus: a report of 10 cases. Immunopharmacology and Immunotoxicology, 2020, 42, 56-58.	1.1	22
51	Prurigo pigmentosa: An underdiagnosed disease in patients of Iranian descent?. Journal of the American Academy of Dermatology, 2006, 55, 131-136.	0.6	20
52	Lipoid proteinosis: phenotypic heterogeneity in Iranian families with c.507delT mutation in <i><scp>ECM</scp>1</i> . Experimental Dermatology, 2015, 24, 220-222.	1.4	20
53	Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study. Journal of Dermatological Treatment, 2021, 32, 33-40.	1.1	20
54	Immunosuppressive drugs for patients with psoriasis during the COVID â€19 pandemic era. A review. Dermatologic Therapy, 2021, 34, e14498.	0.8	20

#	Article	IF	CITATIONS
55	Evaluation of antioxidant enzyme activity and antioxidant capacity in patients with newly diagnosed pemphigus vulgaris. Clinical and Experimental Dermatology, 2015, 40, 313-317.	0.6	19
56	Koebner phenomenon in pemphigus vulgaris patients. JAAD Case Reports, 2016, 2, 419-421.	0.4	19
57	KRT5 and KRT14 Mutations in Epidermolysis Bullosa Simplex with Phenotypic Heterogeneity, and Evidence of Semidominant Inheritance in a Multiplex Family. Journal of Investigative Dermatology, 2016, 136, 1897-1901.	0.3	19
58	Autosomal recessive congenital ichthyosis: CERS3 mutations identified by a next generation sequencing panel targeting ichthyosis genes. European Journal of Human Genetics, 2017, 25, 1282-1285.	1.4	19
59	Effects of L-carnitine supplementation on biomarkers of oxidative stress, antioxidant capacity and lipid profile, in patients with pemphigus vulgaris: a randomized, double-blind, placebo-controlled trial. European Journal of Clinical Nutrition, 2018, 72, 99-104.	1.3	19
60	Epidermodysplasia Verruciformis: Genetic Heterogeneity and EVER1 and EVER2 Mutations Revealed by Genome-Wide Analysis. Journal of Investigative Dermatology, 2019, 139, 241-244.	0.3	19
61	Genomeâ€wide single nucleotide polymorphismâ€based autozygosity mapping facilitates identification of mutations in consanguineous families with epidermolysis bullosa. Experimental Dermatology, 2019, 28, 1118-1121.	1.4	19
62	Desmoglein ELISA in the diagnosis of pemphigus and its correlation with the severity of pemphigus vulgaris. Iranian Journal of Allergy, Asthma and Immunology, 2009, 8, 53-6.	0.3	19
63	Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report. Journal of Dermatological Treatment, 2020, 31, 446-447.	1.1	18
64	Direct immunofluorescence of plucked hair for evaluation of immunologic remission in pemphigus vulgaris. Journal of the American Academy of Dermatology, 2011, 65, e173-e177.	0.6	17
65	Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases. International Immunopharmacology, 2019, 71, 40-42.	1.7	17
66	A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns. Immunopharmacology and Immunotoxicology, 2021, 43, 507-518.	1.1	17
67	Neurological diseases and bullous pemphigoid: A case–control study in Iranian patients. Indian Journal of Dermatology, Venereology and Leprology, 2017, 83, 195.	0.2	16
68	Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult―toâ€ŧreat disease or a consequence of late rituximab initiation?. Dermatologic Therapy, 2022, 35, e15249.	0.8	16
69	The association between <scp>ST</scp> 18 gene polymorphism and severe pemphigus disease among Iranian population. Experimental Dermatology, 2018, 27, 1395-1398.	1.4	15
70	Biallelic KRT5 mutations in autosomal recessive epidermolysis bullosa simplex, including a complete human keratin 5 "knock-out― Matrix Biology, 2019, 83, 48-59.	1.5	15
71	Oral Candida colonization and plaque type psoriasis: Is there any relationship?. Journal of Investigative and Clinical Dentistry, 2018, 9, e12335.	1.8	14
72	Treatment of port wine stains with 595-nm pulsed dye laser in 27 pediatric patients: A prospective study in the Iranian population. Journal of Cosmetic and Laser Therapy, 2019, 21, 373-377.	0.3	14

#	Article	IF	CITATIONS
73	A comparative study of antibody titers of blister fluid and serum in patients with subepidermal immunobullous diseases. International Journal of Dermatology, 2004, 43, 348-351.	0.5	13
74	Fatal Paraneoplastic Pemphigus After Removal of Castleman's Disease in a Child. Pediatric Dermatology, 2012, 29, 656-657.	0.5	13
7 5	Salivary Desmoglein Enzyme-Linked Immunosorbent Assay for Diagnosis of Pemphigus Vulgaris: A Noninvasive Alternative Test to Serum Assessment. BioMed Research International, 2015, 2015, 1-7.	0.9	13
76	Attenuation of serotonin-induced itch by sumatriptan: possible involvement of endogenous opioids. Archives of Dermatological Research, 2018, 310, 165-172.	1.1	13
77	Trichloroacetic acid as a treatment for persistent oral mucosal lesions in pemphigus vulgaris. Journal of the American Academy of Dermatology, 2019, 80, e51-e52.	0.6	13
78	Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus 0.1% for the treatment of frontal fibrosing alopecia: a randomized controlled trial. Journal of Dermatological Treatment, 2022, 33, 284-290.	1.1	13
79	Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients. Journal of Dermatological Treatment, 2022, 33, 869-874.	1.1	13
80	The effect of conventional immunosuppressive therapy on cytokine serum levels in pemphigus vulgaris patients. Iranian Journal of Allergy, Asthma and Immunology, 2014, 13, 174-83.	0.3	13
81	Diffuse plane xanthoma in an otherwise healthy woman. Clinical and Experimental Dermatology, 2001, 26, 405-407.	0.6	12
82	The association of pyoderma faciale and erythema nodosum. Clinical and Experimental Dermatology, 2007, 32, 275-277.	0.6	12
83	Comparison of topical 8-methoxypsoralen and narrowband ultraviolet B with narrowband ultraviolet B alone in treatment-resistant sites in plaque-type psoriasis: a placebo-controlled study. Photodermatology Photoimmunology and Photomedicine, 2011, 27, 294-296.	0.7	12
84	Loss of normal anagen hair in pemphigus vulgaris. Clinical and Experimental Dermatology, 2015, 40, 485-488.	0.6	12
85	Diagnostic accuracy of BP180 NC16a and BP230-C3 ELISA in serum and saliva of patients with bullous pemphigoid. Clinical and Experimental Dermatology, 2015, 40, 324-330.	0.6	12
86	Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. Dermatologic Therapy, 2018, 31, e12671.	0.8	12
87	Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris. International Journal of Women's Dermatology, 2020, 6, 306-310.	1.1	12
88	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	2.0	12
89	Direct immunofluorescence for immunobullous and other skin diseases. Expert Review of Clinical Immunology, 2015, 11, 589-596.	1.3	11
90	Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months. Journal of Dermatological Treatment, 2019, 30, 346-349.	1.1	11

#	Article	IF	CITATIONS
91	Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naÃ-ve and previously treated patients with pemphigus vulgaris after receiving rituximab. International Journal of Women's Dermatology, 2019, 5, 372-377.	1.1	11
92	The efficacy of rituximab in patients with mucous membrane pemphigoid. Journal of Dermatological Treatment, 2022, 33, 1084-1090.	1.1	11
93	Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. Dermatologic Therapy, 2021, 34, e14633.	0.8	11
94	COVID-19: The experience from Iran. Clinics in Dermatology, 2021, 39, 23-32.	0.8	11
95	Evaluation of Vitamin D Status in Newly Diagnosed Pemphigus Vulgaris Patients. Iranian Journal of Public Health, 2014, 43, 1544-9.	0.3	11
96	Pemphigus vulgaris activity score and assessment of convergent validity. Acta Medica Iranica, 2013, 51, 224-30.	0.8	11
97	The dual nature of retinoic acid in pemphigus and its therapeutic potential: Special focus on all-trans Retinoic Acid. International Immunopharmacology, 2016, 36, 180-186.	1.7	10
98	Effects of <scp> </scp> â€carnitine supplementation on cardiovascular and bone turnover markers in patients with pemphigus vulgaris under corticosteroids treatment: A randomized, doubleâ€blind, controlled trial. Dermatologic Therapy, 2019, 32, e13049.	0.8	10
99	Singleâ€nucleotide polymorphisms associated with pemphigus vulgaris: Potent markers for better treatment and personalized medicine. International Journal of Immunogenetics, 2020, 47, 41-49.	0.8	10
100	Adverse outcome and severity of <scp>COVID</scp> 9 in patients with autoimmune bullous diseases: A historical cohort study. Dermatologic Therapy, 2022, 35, .	0.8	10
101	Case Report. An unusual case of cutaneous sporotrichosis and its response to weekly fluconazole. Mycoses, 2000, 43, 75-77.	1.8	9
102	Abortive aphthousâ€like oral lesions: an underreported initial presentation of pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 157-159.	1.3	9
103	Skin Cancer: Genetics, Immunology, Treatments, and Psychological Care. , 2017, , 851-934.		9
104	Interâ€rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2327-2333.	1.3	9
105	The influence of systemic therapy on the serum levels of ILâ \in 6 and ILâ \in 8 in pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 387-390.	1.3	8
106	Pemphigus vulgarisâ€associated Kaposi's sarcoma: response to paclitaxel and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 987-994.	1.3	8
107	Anagen hair loss, antiâ€desmoglein 1, and pemphigus disease area index: a significant relationship?. JDDG - Journal of the German Society of Dermatology, 2017, 15, 946-948.	0.4	8
108	Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial. International Journal of Women's Dermatology, 2018, 4, 87-90.	1.1	8

#	Article	IF	CITATIONS
109	Clinical and Serological Characterization of Orf-Induced Immunobullous Disease. JAMA Dermatology, 2022, 158, 670.	2.0	8
110	Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial. International Journal of Women's Dermatology, 2017, 3, 107-110.	1.1	7
111	Evaluating the efficacy and safety of topical sirolimus 0.2% cream as adjuvant therapy with pulsed dye laser for the treatment of port wine stain: A randomized, doubleâ€blind, placeboâ€controlled trial. Journal of Cosmetic Dermatology, 2021, 20, 2498-2506.	0.8	7
112	Treatment concerns for bullous pemphigoid in the <scp>COVID</scp> â€19 pandemic era. Dermatologic Therapy, 2020, 33, e13956.	0.8	7
113	Current status and prospects for the diagnosis of pemphigus vulgaris. Expert Review of Clinical Immunology, 2021, 17, 819-834.	1.3	7
114	Osteoporosis in patients with Pemphigus Vulgaris before steroid therapy. Acta Medica Iranica, 2014, 52, 879-83.	0.8	7
115	Evaluating the riskâ€toâ€benefit ratio of using cotrimoxazole as a pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: A retrospective study with 494 patients. Dermatologic Therapy, 2022, 35, e15257.	0.8	7
116	Assessment of the therapeutic benefit of oral prednisolone and common adjuvant therapy in stage II of randomized controlled trial study for management of pemphigus vulgaris. Archives of Iranian Medicine, 2014, 17, 626-8.	0.2	7
117	Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy. International Journal of Women's Dermatology, 2022, 8, e038.	1.1	7
118	Follicular dystrophy of immunosuppression. Journal of the American Academy of Dermatology, 2005, 52, 540.	0.6	6
119	<scp>P</scp> araneoplastic pemphigus associated with inflammatory myofibroblastic tumour of the mediastinum: A favourable response to treatment and review of the literature. Australasian Journal of Dermatology, 2015, 56, 120-123.	0.4	6
120	Longitudinal melanonychia in an Iranian population: a study of 96 patients. International Journal of Women's Dermatology, 2016, 2, 49-52.	1.1	6
121	Blockage of T Cell Activation via Antiâ€ <scp>CD</scp> 40 and Antiâ€ <scp>CD</scp> 154 Monoclonal Antibodies can Possibility Treat Alopecia Areata. Scandinavian Journal of Immunology, 2016, 83, 463-464.	1.3	6
122	Traumaâ€induzierter Pemphigus: eine Fallserie von 36ÂPatienten. JDDG - Journal of the German Society of Dermatology, 2016, 14, 166-172.	0.4	6
123	Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital. International Immunopharmacology, 2020, 89, 107093.	1.7	6
124	Desquamative gingivitis in a pemphigus vulgaris patient resistant to rituximab. Dermatologic Therapy, 2020, 33, e13225.	0.8	6
125	The evaluation of efficacy of atmospheric pressure plasma in diabetic ulcers healing: A randomized clinical trial. Dermatologic Therapy, 2021, 34, e15169.	0.8	6
126	Exacerbation of Autoimmune Bullous Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Is There Any Association?. Frontiers in Medicine, 0, 9, .	1.2	6

#	Article	IF	CITATIONS
127	Prednisolone dosage in pemphigus vulgaris. Journal of the American Academy of Dermatology, 2005, 53, 546.	0.6	5
128	Hepatotoxicity and liver enzyme alteration in patients with immunobullous diseases receiving immunosuppressive therapy. Journal of Dermatology, 2011, 38, 1153-1157.	0.6	5
129	Rituximab Induced Neutropenia in a Patient with Bullous Pemphigoid. Archives of Medicine, 2017, 09, .	0.2	5
130	Comparison of ethylenediaminetetraacetic acid-treated desmoglein ELISA and conventional desmoglein ELISA in the evaluation of pemphigus vulgaris in remission. Journal of the American Academy of Dermatology, 2018, 79, 768-770.	0.6	5
131	The potential roles of herpesvirus and cytomegalovirus in the exacerbation of pemphigus vulgaris. Dermatology Practical and Conceptual, 2018, 8, 262-271.	0.5	5
132	The effect of <scp>l</scp> â€carnitine supplementation on serum levels of omentinâ€1, visfatin and SFRP5 and glycemic indices in patients with pemphigus vulgaris: A randomized, doubleâ€blind, placeboâ€controlled clinical trial. Phytotherapy Research, 2020, 34, 859-866.	2.8	5
133	Family impact of pemphigus disease in an Iranian population using the Family Dermatology Life Quality Index. International Journal of Women's Dermatology, 2020, 6, 409-413.	1.1	5
134	Decreased serum levels of interleukinâ€17, interleukinâ€23, <scp>TGF</scp> â€Î² in pemphigus vulgaris patients, and their association with disease phase. Dermatologic Therapy, 2020, 33, e14071.	0.8	5
135	Intralesional injection of biosimilar rituximab in recalcitrant mucocutaneous lesions of patients with pemphigus vulgaris: A pilot study. Dermatologic Therapy, 2020, 33, e14407.	0.8	5
136	Switching from pemphigus vulgaris to psoriasis: a rare report of three cases. International Journal of Dermatology, 2020, 59, e144-e146.	0.5	5
137	Pustular eruption after biosimilar rituximab infusion: report of acute generalized exanthematous pustulosis in two patients with pemphigus. International Journal of Dermatology, 2022, 61, e14-e17.	0.5	5
138	Anal Involvement in Pemphigus Vularis. Autoimmune Diseases, 2013, 2013, 1-4.	2.7	4
139	Characteristic features of cutaneous melanoma in a dermatology referral centre in Tehran, Iran. Australasian Journal of Dermatology, 2017, 58, e228-e231.	0.4	4
140	Treatment of basal cell carcinoma: is intralesional methotrexate an option?. Journal of Dermatological Treatment, 2018, 29, 745-746.	1.1	4
141	Coexistence of oral lichen planus and pemphigus vulgaris. Clinical Oral Investigations, 2018, 22, 2953-2955.	1.4	4
142	Assessing the correlation between trichoscopic features in lichen planopilaris and lichen planopilaris activity index. Australasian Journal of Dermatology, 2019, 60, 214-218.	0.4	4
143	Annular lichenoid dermatitis of youth: report on two adult cases and one child. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1173-1176.	0.4	4
144	Postâ€orf epidermolysis bullosa acquisita. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e118-e119.	1.3	4

#	Article	IF	CITATIONS
145	Treatment of pemphigus patients in the $\langle scp \rangle COVID \langle scp \rangle$ $\hat{a} \in 19$ era: A specific focus on rituximab. Dermatologic Therapy, 2020, 33, e14188.	0.8	4
146	Authors' reply to the comment "Treatment considerations for patients with pemphigus during the COVID-19 pandemic― Journal of the American Academy of Dermatology, 2021, 84, e61-e62.	0.6	4
147	Paradoxical worsening of pemphigus after rituximab presenting as figurate bullous eruption. British Journal of Dermatology, 2021, 185, e2.	1.4	4
148	Correlation of antiâ€Î³/ε nicotinic acetylcholine receptor antibody levels with antiâ€desmoglein 1,3 antibody levels and disease severity in pemphigus vulgaris. Clinical and Experimental Dermatology, 2021, 46, 1230-1235.	0.6	4
149	Serum selenium, zinc, and copper in early diagnosed patients with pemphigus vulgaris. Iranian Journal of Public Health, 2012, 41, 105-9.	0.3	4
150	Pemphigus patients with initial negative levels of antiâ€desmoglein: A subtype with different profile?. Dermatologic Therapy, 2022, 35, e15299.	0.8	4
151	Comparison of the efficacy and safety of 308â€nm excimer laser with intralesional corticosteroids for the treatment of alopecia areata: A randomized controlled study. Lasers in Surgery and Medicine, 2022, 54, 502-510.	1.1	4
152	Dermoscopic Evaluation of Longitudinal Melanonychia in Children: A Prospective Study. Indian Journal of Dermatology, 2021, 66, 445.	0.1	4
153	Evaluation of prolactin levels in patients with newly diagnosed pemphigus vulgaris and its correlation with pemphigus disease area index. International Journal of Women's Dermatology, 2016, 2, 53-55.	1.1	3
154	Complex Interaction Between Diphenylcyclopropenone and Immune Responses in Alopecia Areata. Scandinavian Journal of Immunology, 2016, 84, 310-311.	1.3	3
155	Cheilitis in acne vulgaris patients with no previous use of systemic retinoid products. Australasian Journal of Dermatology, 2017, 58, 211-213.	0.4	3
156	Bullous pemphigoid with linear lesions and antibodies exclusively against the soluble ectodomain of BP180 (LADâ€1). JDDG - Journal of the German Society of Dermatology, 2019, 17, 933-935.	0.4	3
157	Otophyma in a woman: A rare and neglected clinicopathological entity. Australasian Journal of Dermatology, 2019, 60, e337-e338.	0.4	3
158	Adverse electrocardiographic effects of rituximab infusion in pemphigus patients. Dermatologic Therapy, 2020, 33, e14299.	0.8	3
159	Investigating expression pattern of eight immuneâ€related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. Dermatologic Therapy, 2020, 33, e14380.	0.8	3
160	Comparing efficacy and safety of potassium hydroxide 5% solution with 5-fluorouracil cream in patients with actinic keratoses: a randomized controlled trial. Journal of Dermatological Treatment, 2022, 33, 1376-1382.	1.1	3
161	Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies. BMC Dermatology, 2020, 20, 13.	2.1	3
162	Clinical and dermatoscopic characteristics of lichen planusâ€like keratosis in a Westâ€Asian population. Australasian Journal of Dermatology, 2021, 62, e55-e61.	0.4	3

#	Article	IF	CITATIONS
163	Lichen planusâ€like lesions in 36 patients with pemphigus: A crossâ€sectional study. Oral Diseases, 2021, 27, 947-951.	1.5	3
164	Decreased Sox2 messenger RNA expression in basal cell carcinoma. Indian Journal of Dermatology, 2020, 65, 178.	0.1	3
165	Evaluation of Patients Visiting the Dermatology Emergency Unit of a University Dermatology Hospital in Tehran, Iran. Acta Medica Iranica, 2017, 55, 705-711.	0.8	3
166	Retrospective study of gingival involvement in pemphigus: A difficult to treat phenomenon. Dermatologic Therapy, 2022, 35, e15475.	0.8	3
167	Factors associated with the healing time of pemphigus vulgaris oral lesions: A prospective study. Oral Diseases, 2023, 29, 2248-2255.	1.5	3
168	Temporal course of avascular femoral head necrosis in patients with pemphigus vulgaris. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1016-1021.	0.4	2
169	"Change over time in the treatment of pemphigus vulgaris between 2004 and 2016 in Iran†A multiple crossâ€sectional study. Dermatologic Therapy, 2019, 32, e12827.	0.8	2
170	Evaluation of the possible association between acantholysis and antiâ€desmogleins 1 and 3 values in pemphigus vulgaris and pemphigus foliaceus. Journal of Cutaneous Immunology and Allergy, 2019, 2, 169-173.	0.2	2
171	Angina bullosa haemorrhagicaâ€ike lesions in pemphigus vulgaris. Australasian Journal of Dermatology, 2019, 60, e105-e108.	0.4	2
172	Transition between pemphigus vulgaris and pemphigus foliaceus: a 10â€year followâ€up study. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1302-1304.	0.4	2
173	Concomitant bullous pemphigoid and palmoplantar keratoderma: A report of three cases and review of literature. Dermatologic Therapy, 2020, 33, e14481.	0.8	2
174	An unusual case of multibacillary lepros y mimicking prurigo nodularis. Clinical Case Reports (discontinued), 2020, 8, 1234-1237.	0.2	2
175	Drug Sensitivity Profile of Fungi Isolated from Onychomycosis Patients and Evaluation of Squalene Epoxidase Mutation in One Terbinafine-Resistant <i>Trichophyton mentagrophytes</i> Species. Microbial Drug Resistance, 2021, 27, 1658-1663.	0.9	2
176	Punctate Pattern and Pemphigus. American Journal of Dermatopathology, 2021, Publish Ahead of Print, 98-102.	0.3	2
177	Rituximab therapy improves recalcitrant Pemphigus vulgaris. EXCLI Journal, 2015, 14, 109-16.	0.5	2
178	Evaluation of Autoimmune Bullous Diseases in Elderly Patients in Iran: A 10-Year Retrospective Study. Skinmed, 2017, 15, 175-180.	0.0	2
179	A 10â€year survey on Lichen planus pemphigoides in Iran: a therapeutic conundrum. Dermatologic Therapy, 2022, , e15387.	0.8	2
180	How Do Experts Treat Patients with BullousÂPemphigoid around the World? AnÂInternational Survey. JID Innovations, 2022, 2, 100129.	1.2	2

#	Article	IF	CITATIONS
181	Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men. International Journal of Women's Dermatology, 2022, 8, e004.	1.1	2
182	Assessment of healthâ€related quality of life in patients with frontal fibrosing alopecia. Journal of Cosmetic Dermatology, 2022, 21, 6169-6173.	0.8	2
183	Superficial plantar angiomyxoma in a young man. Australasian Journal of Dermatology, 2017, 58, 241-242.	0.4	1
184	Upregulation of SNAI2 and SOX9 mRNA versus downregulation of eight other EMT/stemness related genes in basal cell carcinoma. British Journal of Dermatology, 2019, 181, 1065-1066.	1.4	1
185	Successful treatment of a patient with multicolored nevus of Ota using a combination of 1064 and 532 nm Q-switched Nd:YAG lasers. Journal of Cosmetic and Laser Therapy, 2020, 22, 27-29.	0.3	1
186	Rituximab monotherapy in mild pemphigus. Journal of Dermatological Treatment, 2022, 33, 1784-1786.	1.1	1
187	Diagnostic value of cytology in oral ulcer and comparison with histopathology and direct immunofluorescence. Dermatologic Therapy, 2020, 33, e13929.	0.8	1
188	Pemphigus scalp lesions: is trichoscopy helpful in clinical diagnosis?. International Journal of Dermatology, 2021, 60, 81-87.	0.5	1
189	Epidermolysis bullosa acquisita: the most frequent pemphigoid disease in patients with dermal binding autoantibodies by indirect immunofluorescence microscopy on human saltâ€split skin in Tehran, Iran. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e370-e372.	1.3	1
190	Efficacy and safety of hydrogen peroxide topical solution in treating actinic keratosis: A randomized controlled trial. Dermatologic Therapy, 2021, 34, e15097.	0.8	1
191	A case of hidroacanthoma simplex with new dermoscopic features. Indian Journal of Dermatology, Venereology and Leprology, 2019, 85, 319.	0.2	1
192	Ulcerated necrobiosis lipoidica: A cutaneous granulomatous reaction associated with systemic B-cell lymphoma. Indian Journal of Dermatology, Venereology and Leprology, 2018, 84, 481.	0.2	1
193	A Case of Lepromatous Leprosy Masquerading As Vasculitis. Dermatology Practical and Conceptual, 2019, 9, 222-224.	0.5	1
194	â€~Mucocutaneous' or â€~cutaneomucosal' interval: which one is longer in pemphigus vulgaris?. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 526-527.	1.3	0
195	Zeitlicher Verlauf der avaskulän Nekrose des Hüftkopfes bei Patienten mit Pemphigus vulgaris. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1016-1022.	0.4	0
196	386 Novel FERMT1 mutations in Kindler syndrome and its association with adermatoglyphia. Journal of Investigative Dermatology, 2016, 136, S68.	0.3	0
197	Persistent lip enlargement: An unusual presentation of lupus erythematosus. International Journal of Women's Dermatology, 2017, 3, 96-99.	1.1	0
198	511 Autosomal recessive congenital ichthyosis: CERS3 mutations identified by a next generation sequencing array targeting ichthyosis genes. Journal of Investigative Dermatology, 2017, 137, S88.	0.3	0

#	Article	IF	CITATIONS
199	523 Disease-targeted next generation sequencing identifies mutations in consanguineous families with phenotypic spectrum of ichthyoses. Journal of Investigative Dermatology, 2017, 137, S90.	0.3	O
200	Anagener Haarverlust, Antiâ€Desmoglein 1 und Pemphigus Disease Area Index: Ein signifikanter Zusammenhang?. JDDG - Journal of the German Society of Dermatology, 2017, 15, 945-947.	0.4	0
201	509 Disease-targeted next generation sequencing identifies mutations in patients with epidermolysis bullosa. Journal of Investigative Dermatology, 2017, 137, S87.	0.3	0
202	Reply to: "Comment on â€Trichloroacetic acid as a treatment for persistent oral mucosal lesions in pemphigus vulgaris'― Journal of the American Academy of Dermatology, 2019, 81, e141.	0.6	0
203	Multiple giant milia in cutaneous squamous cell carcinoma: A rare presentation. Australasian Journal of Dermatology, 2020, 61, 163-164.	0.4	O
204	Chronic subungual lesion in a young woman. Indian Journal of Dermatology, Venereology and Leprology, 2021, 87, 439-441.	0.2	0
205	Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, but Not Chronic Patients With Inactive Disease Compared to Healthy Controls. Dermatology Practical and Conceptual, 2021, 11, e2021035.	0.5	O
206	Patchy Alopecia in a Patient with Rheumatoid Arthritis: A Practical Application of Trichoscopy. Case Reports in Dermatology, 2021, 13, 42-46.	0.3	0
207	Köbner Phenomenon in a Rituximab-Treated Pemphigus Patient: Beware Disease Activity. Dermatology Practical and Conceptual, 2019, 9, 320-321.	0.5	O
208	Selfâ€assessment Pemphigus Vulgaris Activity Score (<scp>SAâ€PVAS</scp>): A new tool for patients to selfâ€assess their disease severity. Australasian Journal of Dermatology, 2022, , .	0.4	0
209	Indirect immunofluorescence on rat bladder epithelium inÂpatients with pemphigus vulgaris with an extended followâ€up. Skin Health and Disease, 0, , .	0.7	O